Investors in Research

Monograph Capital is a venture firm focused on life sciences. With a dedicated emphasis on the life sciences sector, Monograph Capital invests in innovative companies and technologies that aim to advance healthcare and biotechnology. The firm supports early-stage ventures as well as growth-stage companies, providing critical capital, strategic guidance, and industry expertise to drive their development and success. Monograph Capital's investments span across biotech, pharmaceuticals, medical devices, and other areas within the life sciences field, aiming to contribute to breakthrough discoveries, therapies, and medical advancements. Through its strategic investments, Monograph Capital plays a crucial role in accelerating innovation and improving health outcomes globally.

Vlasroot is an informal investor group targeting SMEs with growth potential, proven track records, and strong management teams. They specialize in companies solving tangible problems, leveraging their extensive business and investment expertise to foster growth and help achieve strategic milestones through co-creation and network support.

SIS Ventures is dedicated to investing in impact-led enterprises that aim to address society's most pressing challenges and needs. By supporting innovative startups and businesses with a strong social mission, SIS Ventures fosters solutions that drive positive change in communities and the environment. They provide strategic capital and guidance to help these enterprises scale their impact, contributing to a more equitable and sustainable future.

ETFS Capital is an investment company specializing in securities within the monetary facts and management sectors. They focus on providing investment opportunities that align with strategic goals in these sectors, offering a range of securities and management solutions tailored to meet the needs of institutional and individual investors. ETFS Capital aims to deliver value through expert management and strategic allocation of assets, contributing to the growth and stability of client portfolios in the financial sector.

The ALS Investment Fund supports and finances biotech companies that develop drugs and diagnostics for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease. The ALS Investment Fund was initiated by Dutch ALS patients and is advised by a top-tier European VC firm, Life Sciences Partners. The ALS Investment Fund invests globally, but focuses on Europe and the US. The fund brings depth of disease-specific knowledge and a deep network in the space.

The Future Food Fund is an early-stage venture capital impact fund focused on investing in food and agriculture companies in North West Europe. Their primary objective is to support and accelerate the transition towards sustainable food systems. By investing in innovative startups in the food and agriculture sectors, the Future Food Fund aims to drive positive environmental and social impact while fostering economic growth. The fund targets companies that are developing groundbreaking solutions to enhance sustainability, reduce waste, and improve efficiency in food production and distribution. By providing essential capital and strategic support, the Future Food Fund empowers entrepreneurs to create scalable and impactful solutions that address the pressing challenges facing the global food system. Through their investments, they are committed to promoting a more sustainable and resilient food ecosystem for future generations.

Advent Life Sciences is a venture capital firm dedicated to investing in life sciences businesses. Focusing on innovative companies in biotechnology, pharmaceuticals, medical devices, and diagnostics, Advent Life Sciences supports the development of breakthrough technologies and therapies. By providing capital and strategic expertise, the firm helps entrepreneurs navigate the complexities of the life sciences sector, accelerating the path from research to market. Advent Life Sciences is committed to advancing healthcare solutions that improve patient outcomes and address unmet medical needs globally.

MVM Life Science Partners, we are a specialized healthcare investment firm focused on early-stage and growth-stage companies in the life sciences sector. Founded in 1997 and headquartered in London, our firm invests globally in innovative biopharmaceuticals, medical technology, diagnostics, and digital health companies. Our approach combines deep sector expertise with strategic support to help our portfolio companies achieve their full potential. We have a strong track record of supporting groundbreaking therapies and technologies that make a significant impact on healthcare outcomes worldwide.

HS LifeSciences was established in 2008 by seasoned biotech entrepreneurs with many years of experience in managing biotech companies. The lessons learned over the years have been distilled into a new business model centered on the foundation and growth of new life sciences companies without the need for conventional multiple rounds of equity-based financing.

Praetura are a venture capital firm in the North West, who invest in early-stage businesses and provide 'more than money' support. We have developed a reputation for being a supportive and proactive investor who injects more than just capital. We can evidence the value from our differentiated approach from both investment returns and testament from our portfolio companies. Our partnered entrepreneurs embrace the shoulder to shoulder Praetura approach and utilise our experience and resource to maximise their businesses’ potential.

Valide.no supports researchers and entrepreneurs in commercializing innovative solutions with expertise, networking, and capital, contributing to a better world through research-based products and ideas

Birk Venture is a company based in Oslo, Norway, dedicated to transforming unique innovations and technologies into successful businesses in the healthcare sector. They focus on leveraging cutting-edge technologies in life science to meet the increasin.